In June 2026, both the crypto market and the tech sector are undergoing intense price revaluations. According to Gate market data, Bitcoin (BTC) closed at $62,422.0 as of June 23, down 2.88% over 24 hours, with a 7-day cumulative drop of 7.63%, a 33.74% decline over the past year, and a market cap of around $1.25 trillion. Meanwhile, on the traditional finance side, quantum computing has become a focal point for institutional capital. On June 22, UBS released a research report predicting that Quantum Advantage—the point at which quantum computers surpass classical supercomputers in solving real-world tasks—could arrive around 2039.
While this timeline is slightly more conservative than some industry optimists, UBS’s assessment offers capital markets a quantifiable long-term benchmark. More importantly, the report specifically lists four pure-play quantum computing companies as key institutional watchlist names: IonQ (IONQ), D-Wave Quantum (QBTS), Rigetti Computing (RGTI), and Quantum Computing Inc. (QUBT). At the same time, UBS notes that major tech giants such as IBM, Alphabet (Google), Microsoft, Amazon, and Nvidia are also deeply involved in building quantum computing infrastructure, providing a distinctly different risk-return profile for investors.
Quantum Advantage in 2039: The Core Logic Behind UBS’s Assessment
UBS’s projection for quantum advantage in 2039 isn’t based on a single technological breakthrough. Instead, it rests on the gradual accumulation of commercial value from quantum computing across multiple application scenarios. The report highlights the significant potential in biopharmaceuticals: while AI has already accelerated drug discovery to some extent, quantum computing could push these boundaries further—by simulating molecular models and chemical reactions too complex for classical systems to handle.
UBS’s Japan-based pharmaceutical analyst Atushi Seki points out that quantum computing could reduce preclinical drug candidate screening from the traditional 4–5 years and over $100 million in costs to just 12–18 months and only $3–5 million. If realized, this efficiency gain would fundamentally reshape the R&D economic model of the pharmaceutical industry. Beyond biopharma, UBS also identifies AI, cybersecurity, and high-performance computing as major beneficiaries of quantum advantage.
From a technical perspective, UBS’s 2039 forecast falls within the mainstream industry range. Some more optimistic estimates see quantum advantage arriving in the early 2030s, while others push it beyond 2040. UBS’s timeline is neither overly optimistic nor overly conservative—it provides an institutional-grade benchmark, allowing investors to evaluate quantum computing assets within a relatively clear long-term framework.
It’s worth noting that UBS’s earlier analyses have already identified IBM, Alphabet, and Microsoft as leaders in the quantum computing space. Google Quantum AI’s Willow processor (105 qubits) has demonstrated exponential speedup in specific computational tasks, while IBM’s Heron processor (156 qubits) is already deployed in molecular chemistry applications. These technological advances form the foundation of UBS’s outlook.
Four Pure-Play Quantum Computing Stocks: Financial Fundamentals and Market Positioning
The four quantum computing stocks highlighted by UBS differ in business models, technical approaches, and financial performance, but share common traits: high growth, high losses, and high valuation volatility.
IonQ (IONQ) is currently the largest pure-play quantum computing company by revenue. In Q1 2026, IonQ posted GAAP revenue of $64.7 million, up 755% year-over-year, and raised its full-year guidance to $260–$270 million. As of June 23, IONQ closed at $58.905, with an intraday range of $55.53 to $61.99 and a market cap of about $21.769 billion. According to the latest FactSet survey, the median target price among 11 analysts has been raised from $65 to $70, with a high of $100 and a low of $48.5. Of 13 analysts, 10 rate the stock positively, 2 are neutral, and 1 is cautious. However, IONQ’s valuation multiples are eye-catching—a price-to-sales ratio of about 99x, an adjusted EBITDA loss of $97 million in Q1, and negative operating cash flow of $151 million. The trailing P/E is a staggering 648x, and its beta is 4.77, all pointing to extremely high volatility risk.
D-Wave Quantum (QBTS) follows the annealing quantum computing path, differentiating itself from IonQ’s trapped-ion technology. In Q1 2026, QBTS reported revenue of $2.9 million, down 81% year-over-year; however, bookings surged 1,994% to $33.4 million, signaling explosive commercial demand. On June 15, Mizuho Securities raised its target price for QBTS from $29 to $35, maintaining an "outperform" rating. S&P Global reports that 15 analysts have a "strong buy" consensus, with an average target price of $36.84. As of June 22, QBTS traded at about $24.47.
Rigetti Computing (RGTI) specializes in superconducting quantum processors, offering its 108-qubit Cepheus-1-108Q processor through platforms like Amazon Braket, Microsoft Azure Quantum, and qBraid, with a median two-qubit gate fidelity of 99.8%. Q1 revenue was $4.4 million, roughly triple the same period last year. As of June 23, RGTI was priced at $21.38, with an intraday high of $22.475 and a low of $20.405, and a market cap of about $7.107 billion. The average target price from 13 analysts is $29.24, though some have set targets as low as $15. RGTI’s price-to-book ratio is about 12.18x, and it remains deeply unprofitable.
Quantum Computing Inc. (QUBT) is the smallest of the four by market cap, at about $2.377 billion. Q1 revenue was $3.7 million, up from just $39,000 a year earlier, with a per-share loss of $0.02—significantly better than Wall Street’s expected $0.05 loss. As of June 23, QUBT opened at $10.55, trading between $10.45 and $11.30.
Looking at the sector as a whole, these four stocks have risen over 50% since the end of March 2026, driven in part by the US government’s announcement of a $2 billion federal quantum investment. In mid-June, the sector saw a collective rally: QBTS up 13%, QUBT up 12%, RGTI up 10%, and IONQ up 6%. On June 23, following President Trump’s signing of an executive order on quantum technology, after-hours trading saw QBTS jump over 7%, QUBT rise more than 5%, RGTI climb over 4%, and IONQ gain more than 3%. The interplay of policy catalysts and business fundamentals is the main source of volatility for this sector in 2026.
Quantum Strategies of Big Tech: An Alternative Investment Thesis
For investors with lower risk tolerance or those seeking more diversified exposure to quantum computing, the UBS report highlights another path—investing in major tech companies such as IBM, Alphabet, Microsoft, Amazon, and Nvidia.
These companies share several characteristics: quantum computing is only a part of their broader business portfolios; their core revenue streams are stable (cloud computing, AI chips, enterprise software, etc.); and they have ample R&D budgets and talent pools. IBM has announced its Blue Jay system plan—to deploy a 2,000-logical-qubit system by 2033. Google is advancing quantum software and error correction through Quantum AI. Microsoft offers quantum cloud services via Azure Quantum, and Nvidia is focusing on the synergy between quantum systems and classical AI-accelerated computing.
The core of this investment logic is: if the commercialization of quantum computing progresses more slowly than expected, big tech stocks can provide downside protection; if it accelerates, these companies are also well-positioned to benefit. Of course, the trade-off is that their upside potential is much lower than that of pure-play quantum stocks.
Quantum Computing ETFs: Performance in 2026
For investors seeking index-based exposure to the quantum computing theme, ETFs offer another option. The Defiance Quantum ETF (QTUM) delivered a year-to-date return of 54.2% as of June 2, 2026—roughly five times the S&P 500’s gain (11%) and more than double the Nasdaq 100’s return (21%) for the same period. This fund equally weights about 70–80 stocks tracking the BlueStar Machine Learning and Quantum Computing Index, with a 0.40% expense ratio. As of February 2026, QTUM’s assets exceeded $3.5 billion and it has earned a five-star Morningstar rating. The iShares Quantum Computing UCITS ETF (QANT) posted a year-to-date return of 30.79% as of June 18.
The advantage of ETFs is that they diversify away single-stock execution and technology path risks. However, the downside is clear—QTUM’s equal-weight structure means it holds both highly volatile pure quantum computing stocks and relatively stable semiconductor companies, resulting in a blended return profile.
Risk Analysis: High Valuations, Technical Uncertainty, and Commercialization Lag
The rally in quantum computing stocks in 2026 is built on a triple narrative of technological breakthroughs, policy support, and revenue growth. However, several risk factors must be considered from a financial perspective.
Disconnect between valuations and revenue. IonQ’s price-to-sales ratio is about 99x, and Rigetti supports a $7.1 billion market cap on $4.4 million in quarterly revenue. Even assuming these companies can maintain triple-digit revenue growth, current valuations still imply extremely optimistic long-term assumptions. IonQ’s internal forecast sees its market cap reaching $65 billion by 2030, but this projection is itself based on an industry high-growth scenario and carries significant uncertainty.
Technical path uncertainty. Superconducting, trapped-ion, photonic, and neutral atom quantum computing approaches are all evolving in parallel, and it’s still unclear which will achieve fault-tolerant quantum computing first. In the current Noisy Intermediate-Scale Quantum (NISQ) era, quantum processors are not yet able to reliably run practical algorithms. The journey from today’s technology to quantum advantage in 2039 is filled with engineering challenges.
Commercialization lag. UBS’s 2039 forecast is still 13 years away. During this period, these companies must continue heavy R&D investment and ongoing fundraising, while managing the tension between revenue growth and widening losses. IonQ’s Q1 operating cash outflow was $151 million; at this burn rate, continued operations will depend on access to capital markets.
High market volatility. Quantum computing stocks generally have elevated beta coefficients—IONQ’s beta is 4.77. In early 2025, Nvidia CEO Jensen Huang’s comment that "practical quantum computers are still 20 years away" triggered a sharp selloff in quantum stocks. Any shifts in policy, technology, or capital flows can spark intense volatility.
Conclusion
UBS’s 2039 quantum advantage forecast provides a clear long-term benchmark for capital markets. In 2026, IONQ, QBTS, RGTI, and QUBT have entered the broader institutional spotlight as pure-play quantum computing stocks, while IBM, Alphabet, Microsoft, and other tech giants offer a distinctly different risk-return profile for participation. The strong performance of quantum computing ETFs like QTUM (54% return year-to-date in 2026) further confirms that market interest in this theme is heating up rapidly.
However, high valuations, technical uncertainty, a lengthy commercialization timeline, and extreme share price volatility remain critical constraints for this investment theme. Whether quantum computing will truly achieve quantum advantage by 2039—and which companies will ultimately benefit—are questions that will take over a decade to answer. For investors, the key is to distinguish between "narrative" and "fundamentals," and to make allocation decisions based on a thorough understanding of the risks and their own risk tolerance.
